Skip to search formSkip to main contentSkip to account menu

BRL 32872

Known as: BRL-32872 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Benzamides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Anti-arrhythmic Effects of INa, IKr, and Combined IKr–ICaL Blockade in an Experimental Model of Acute Stretch-Related Atrial Fibrillation
IntroductionAtrial dilatation is commonly associated with atrial fibrillation (AF), but the electrophysiological mechanisms and… 
Review
2006
Review
2006
The antiarrhythmic drug BRL-32872.
BRL-32872 is a new antiarrhythmic drug with balanced class-III and class-IV actions as categorized by the Vaughan-Williams… 
Highly Cited
2001
Highly Cited
2001
High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872.
Human ether-a-go-go-related gene (HERG) potassium channels are one primary target for the pharmacological treatment of cardiac… 
1999
1999
Electrophysiological characterization of BRL-32872 in canine Purkinje fiber and ventricular muscle. Effect on early after-depolarizations and repolarization dispersion.
1998
1998
Comparative effects of glibenclamide, tedisamil, dofetilide, E-4031, and BRL-32872 on protein kinase A-activated chloride current in guinea pig ventricular myocytes.
The modulation of the protein kinase A-activated chloride current (PKA-I[Cl]) may lead to modification of the cardiac action… 
1998
1998
Synthesis, electrophysiological properties and analysis of structural requirements of a novel class of antiarrhythmic agents with potassium and calcium channel blocking properties.
1998
1998
Combined potassium and calcium channel antagonistic activities as a basis for neutral frequency dependent increase in action potential duration: comparison between BRL-32872 and azimilide.
Highly Cited
1996
Highly Cited
1996
Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872.
In the search for novel antiarrhythmic agents, compounds with a diversity of electrophysiological actions have been suggested to… 
1995
1995
Antifibrillatory effects of BRL-32872 in anesthetized Yucatan minipigs with regional myocardial ischemia.
The antifibrillatory potential of BRL-32872, a novel antiarrhythmic compound with K+ and Ca2+ channel blocking activities, was… 
1995
1995
Electrophysiological effect of BRL-32872, a novel antiarrhythmic agent with potassium and calcium channel blocking properties, in guinea pig cardiac isolated preparations.
The effects of N-(3,4-dimethoxyphenyl)-N-[3[[2-(3,4-dimethoxyphenyl) ethyl] propyl]-4-nitrobenzamide hydrochloride (BRL-32872), a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)